Trial · NCT05833958
Polypill Versus Metformin in New Onset Type 2 Diabetes
NCT05833958, Phase 2, Withdrawn, George Medicines PTY Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Polypill Versus Metformin in New Onset Type 2 Diabetes. Trials, record NCT05833958. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05833958
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polypill Versus Metformin in New Onset Type 2 Diabetes
- NCT number
- NCT05833958
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- George Medicines PTY Limited
- Conditions
- Type 2 Diabetes
- Interventions
- GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin, Metformin, Metformin
- First posted
- 2023-04-27
- Last updated
- 2024-09-19
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in glycosylated haemoglobin (HbA1c) | 16 weeks | Change in glycosylated haemoglobin (HbA1c) from baseline to 16 weeks |
| Secondary | Change in fasting plasma glucose | 16 weeks | Change in fasting plasma glucose from baseline to 16 weeks |
| Secondary | Change in cholesterol | 16 weeks | Change in fasting total cholesterol, LDL-cholesterol and HDL-cholesterol from baseline to 16 weeks |
| Secondary | Change in triglycerides | 16 weeks | Change in fasting triglycerides from baseline to 16 weeks |
| Secondary | Change in blood pressure | 16 weeks | Change in systolic and diastolic blood pressure from baseline to 16 weeks |
| Secondary | Change in weight in kilograms | 16 weeks | Change in weight from baseline to 16 weeks |
| Secondary | Medication adherence | 16 weeks | Medication adherence throughout the trial. Adherence will be assessed by self-report surveys entered directly into the ePRO platform (eCRF). |
| Secondary | Medication tolerability | 16 weeks | Medication tolerability throughout the trial (based on permanent drug cessation due to side effects and incidence of reported side effects). Tolerability will be assessed by recording of adverse effects into self-report surveys, and adverse events identified by the Investigator during study contacts, entered directly into the ePRO platform (eCRF). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05833958
GET https://conductscience.org/api/trials/v1/NCT05833958/registered